| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $20.0M | -48.5% |
| SG&A Expense | $6.7M | +7.3% |
| Operating Income | -$26.7M | +40.7% |
| Net Income | -$24.6M | +56.2% |
| EPS (Basic) | -$2.02 | +67.6% |
| EPS (Diluted) | -$2.31 | +62.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $10.6M | +83.4% |
| Total Assets | $13.9M | +36.4% |
| Current Liabilities | $3.9M | -9.3% |
| Total Liabilities | $4.6M | -74.3% |
| Stockholders' Equity | $9.3M | +220.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$21.9M | +45.2% |
| Financing Cash Flow | $26.7M | +53.9% |